PMID

Data

Article Title

Organization

Rationally designed"dipeptoid" analogues of CCK. A Free-Wilson/Fujita-Ban analysis of some alpha-methyltryptophan derivatives as CCK-B antagonists.

Parke-Davis Neuroscience Research Centre

Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.

James Black Foundation

Second generation"peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile.

Warner-Lambert

Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and"mixed" CCK-A/CCK-B antagonists.

Parke-Davis Neuroscience Research Centre

Amide bond replacements incorporated into CCK-B selective"dipeptoids".

Parke-Davis Neuroscience Research Center

Rationally designed"dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988.

Parke-Davis Neuroscience Research Centre

Rationally designed"dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties.

Parke-Davis Research Unit

Design of non-peptide CCK2 and NK1 peptidomimetics using 1-(2-nitrophenyl)thiosemicarbazide as a novel common scaffold.

Novartis Institute For Medical Sciences

The design and synthesis of the high efficacy, non-peptide CCK1 receptor agonist PD170292.

Ccipe-Faculte De Pharmacie

 

Design and synthesis of a targeted set of aromatic amino acid derivatives for identification of new lead compounds

TBA

 

Synthesis of novel iodinated radioligands with high affinity and selectivity for CCK-B/gastrin receptors

TBA

 

The rational design and synthesis of non-peptide rhegnylogues of CCK-26-33 - a novel series of CCK-A selective ligands

TBA

 

Synthesis of a potent and selective non-peptide CCK-B/gastrin receptor antagonist tritiated ligand.

TBA

 

Cholecystokinin analogues: The ergopeptine alkaloids as models of the active conformation of CCK

TBA

 

Design and synthesis of novel nonpeptide CCK-B receptor antagonists

TBA

 

SAR study of the indole moiety of CI-988, a potent and selective CCK-B antagonist

TBA

 

Synthesis and pharmacological evaluation of highly potent dual histamine H₂ and gastrin receptor antagonists

TBA

 

Design, synthesis, and pharmacological evaluation of dual histamine H₂ and gastrin receptor antagonists

TBA

 

Novel cholecystokinin receptor ligands: Oxopiperazines derived from Boc-CCK-4

TBA

 

Alternative strategies towards the identification of chemical lead compounds by rational design

TBA

 

Methionine replacements in biologically active peptides

TBA

 

α-β-didehydrotryptophan as a surrogate for α-methyltryptophan in CCK ‘peptoids’ related to CI-988.

TBA

 

Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class

TBA

 

Diphenylpyrazolidinone and benzodiazepine cholecystokinin antagonists: A case of convergent evolution in medicinal chemistry

TBA

 

Diastereoselective synthesis of cyclopropyl phenylalanines and their incorporation into dipeptides

TBA

 

Synthesis and sar study of novel CCK-B antagonists

TBA

 

The use of a proline ring as a conformational restraint in CCK-B receptor “dipeptoids”.

TBA

 

The synthesis and CCK receptor affinities of selected carboyxlic acid mimics of CI-988 - a potent and selective CCK-B antagonist

TBA

Discovery of imidazole carboxamides as potent and selective CCK1R agonists.

Merck Research Laboratories

Highly constrained dipeptoid analogues containing a type II' beta-turn mimic as novel and selective CCK-A receptor ligands.

Instituto De QuíMica MéDica (Csic)

Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists.

Parke-Davis Pharmaceutical Research

Cholecystokinin peptidomimetics as selective CCK-B antagonists: design, synthesis, and in vitro and in vivo biochemical properties.

University of Paris

Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists.

James Black Foundation

2,7-Dioxo-2,3,4,5,6,7-hexahydro-1H-benzo[h][1,4]diazonine as a new template for the design of CCK(2) receptor antagonists.

James Black Foundation

Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons.

James Black Foundation

Improving the affinity and selectivity of a nonpeptide series of cholecystokinin-B/gastrin receptor antagonists based on the dibenzobicyclo[2.2.2]octane skeleton.

James Black Foundation

A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane.

James Black Foundation

Quinazolinone cholecystokinin-B receptor ligands.

Eli Lilly

Synthesis and X-ray crystallographic analysis of quinazolinone cholecystokinin/gastrin receptor ligands.

Eli Lilly